Drug
Encenicline clinical trials
Also written EVP-6124 and MT-4666.
- studies test it
- 16
- open now
- 0
- in phase 3
- 7
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2013 (5)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 5
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 1
FORUM Pharmaceuticals Inc (13) · Mitsubishi Tanabe Pharma Corporation (2) · A. Eden Evins (1)
Studies
Open first, then newest update. How each study uses encenicline is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine DependenceTerminatedPhase 2A. Eden EvinsNCT01480232Written as EVP-6124
- A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyCompletedPhase 3FORUM Pharmaceuticals IncNCT01714713Written as EVP-6124
- Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyCompletedPhase 3FORUM Pharmaceuticals IncNCT01716975Written as EVP-6124
- Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyCompletedPhase 3FORUM Pharmaceuticals IncNCT01714661Written as EVP-6124
- Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025TerminatedPhase 3FORUM Pharmaceuticals IncNCT02004392Written as EVP-6124
- Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's DiseaseTerminatedPhase 3FORUM Pharmaceuticals IncNCT01969136Written as Drug: EVP-6124
- Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's DiseaseTerminatedPhase 3FORUM Pharmaceuticals IncNCT01969123Written as Drug: EVP-6124
- Safety Study of MT-4666 in Subjects With Alzheimer's DiseaseTerminatedPhase 3Mitsubishi Tanabe Pharma CorporationNCT02327182Written as MT-4666
- Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving MemantineWithdrawnPhase 2FORUM Pharmaceuticals IncNCT02246075Written as EVP-6124
- Safety and Efficacy of MT-4666CompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT01764243Written as MT-4666
- EVP-6124 Renal Impairment StudyCompletedPhase 1FORUM Pharmaceuticals IncNCT01984723Written as Experimental: EVP-6124
- EVP-6124 Hepatic Impairment StudyCompletedPhase 1FORUM Pharmaceuticals IncNCT01984736Written as Experimental: EVP-6124
- Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2FORUM Pharmaceuticals IncNCT01073228Written as EVP-6124
- Safety and Cognitive Function Study of EVP-6124 in Patients With SchizophreniaCompletedPhase 2FORUM Pharmaceuticals IncNCT00968851Written as EVP-6124
- Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With SchizophreniaCompletedPhase 1FORUM Pharmaceuticals IncNCT01556763Written as EVP-6124 (0.3 mg/day)
- Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's DiseaseCompletedPhase 1FORUM Pharmaceuticals IncNCT00766363Written as EVP-6124 (0.1 mg/day)
Codes
What other systems call encenicline · ClinicalTrials.gg INT006100
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q19904062 | encenicline | One source Wikidata |
| NCI Thesaurus | C166844 | Encenicline | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.